Analysis of the Impacts of Dual Pricing in Spain
inno has on behalf of the kohlpharma GmbM studied the Spanish pharmaceutical market and analyzed the impact of dual pricing on key stakeholders in Spain and on a European level. The report is based on an impact assessment of empirical research such as a meta-analysis of publically available documents and interviews with key stakeholders in the Spanish pharmaceutical market. Through the analysis inno concludes that any limitation of free trade within the single market is harmful to Europe’s sustainable competitiveness, its innovativeness and in addition harmful to European consumers. Spain’s dual pricing system constitutes a danger for the single free market and is legally doubtful. The full repot is found below.
- 2014 - 2015